Data updated: Mar 10, 2026
FUROSEMIDE
FUROSEMIDE
Approved 1979-01-10
49
Indications
--
Phase 3 Trials
47
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1979-01-10
- Routes
- ORAL, INJECTION
- Dosage Forms
- TABLET, INJECTABLE, SOLUTION
Companies
KALAPHARM WATSON LABS IGI LABS INC ANI PHARMS WARNER CHILCOTT Pfizer INTL MEDICATION Hikma Fresenius Kabi ABRAXIS PHARM ASPIRO SMITH AND NEPHEW PHARMOBEDIENT LEADING Apotex GLAND SABA ILAC SANAYIVE PRINSTON INC AVET LIFESCIENCES MICRO LABS IPCA LABS LTD Baxter AMNEAL PHARMS CO Aurobindo Pharma Sun Pharma EPIC PHARMA LLC AM REGENT WATSON LABS TEVA CHARTWELL RX ESJAY PHARMA AREVA PHARMS MEITHEAL PHARMOBEDIENT CNSLTG SAGENT GRAVITI PHARMS MANKIND PHARMA SUPERPHARM EUGIA PHARMA AstraZeneca ACCORD HLTHCARE MARSAM PHARMS LLC
Active Ingredient: FUROSEMIDE
Website: ↗
FUROSEMIDE Approval History
Loading approval history...
What FUROSEMIDE Treats
49 FDA approvalsOriginally approved for its first indication in 1979 . Covers 49 distinct patient populations.
- Other (49)
Other
(49 approvals)- • Approved indication (Jan 1979)
- • Approved indication (May 1981)
- • Approved indication (Aug 1981)
- • Approved indication (Oct 1981)
- • Approved indication (May 1982)
- • Approved indication (May 1982)
- • Approved indication (Jul 1982)
- • Approved indication (Oct 1983)
- • Approved indication (Nov 1983)
- • Approved indication (Nov 1983)
- • Approved indication (Feb 1984)
- • Approved indication (May 1984)
- • Approved indication (Sep 1985)
- • Approved indication (Nov 1985)
- • Approved indication (Jan 1986)
- • Approved indication (Jan 1986)
- • Approved indication (Feb 1986)
- • Approved indication (Oct 1986)
- • Approved indication (Dec 1986)
- • Approved indication (Jan 1987)
- • Approved indication (Apr 1987)
- • Approved indication (Jul 1987)
- • Approved indication (Oct 1987)
- • Approved indication (Jan 1988)
- • Approved indication (Feb 1988)
- • Approved indication (Sep 1990)
- • Approved indication (Aug 1991)
- • Approved indication (Sep 1994)
- • Approved indication (Oct 1994)
- • Approved indication (May 1999)Label Letter
- • Approved indication (Mar 2004)
- • Approved indication (Nov 2005)
- • Approved indication (Sep 2006)
- • Approved indication (Mar 2007)
- • Approved indication (Jan 2014)
- • Approved indication (Apr 2014)
- • Approved indication (Aug 2014)
- • Approved indication (Jul 2016)
- • Approved indication (May 2019)
- • Approved indication (Jul 2020)
- • Approved indication (Dec 2020)
- • Approved indication (Jan 2021)
- • Approved indication (Jan 2022)
- • Approved indication (Oct 2022)
- • Approved indication (Dec 2022)
- • Approved indication (Apr 2024)
- • Approved indication (Dec 2024)
- • Approved indication (Jul 2025) New
- • Approved indication (Jan 2026) New
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FUROSEMIDE FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.